Effect of the Pore Structure of an Apatite-Fiber Scaffold on the Differentiation of P19.CL6 Cells into Cardiomyocytes

Abstract:

We previously reported that P19.CL6 cells can be cultured in porous hydroxyapatite ceramics prepared by firing green compacts consisting of apatite fibers and spherical carbon beads (150 μm in diameter). Cells cultured for 20 days in an apatite-fiber scaffold (AFS) proliferated and differentiated into cells expressing troponin T, a cardiomyocyte-specific gene, but the expression level was insufficient to support the functional maturation of cells required for biomedical device applications. In this study, we aimed to optimize the internal AFS environment for cardiomyocytes by mixing two sizes (150-and 20-μm) of carbon beads. P19.CL6 cells were cultured in AFS materials comprising different carbon ratios in the presence of alpha-MEM with (AFS+) or without (AFS-) dimethyl sulfoxide (DMSO), and cell growth and gene expression were assessed. We found that AFS(50, 1:1 ratio) is the most suitable scaffold for the proliferation and differentiation of P19.CL6 cells and the addition of DMSO to the culture medium is necessary for differentiation into cardiomyocytes. We also assessed the culture of P19.CL6 cells in AFS in a radial-flow bioreactor for several days.

• Periodical: Key Engineering Materials (Volume 782)
• Pages: 116-123
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.782.116
• Online since: October 2018
• Authors: Yuzuha Ichikawa, Kei Yasuda, Masahiro Takahara, Mamoru Aizawa, Nobuyuki Kanzawa*
• Keywords: Cardiomyocyte, Hydroxyapatite, Scaffold, Tissue Engineering

References

[1] A.L. Harvey, Natural products in drug discovery, Drug Discov. Today 13 (2008) 894-901.

DOI: 10.1016/j.drudis.2008.07.004

[2] B. Shen, A new golden age of natural products drug discovery, Cell 163 (2015) 1297-1300.

DOI: 10.1016/j.cell.2015.11.031

[3] O. Kepp, L. Galluzzi, M. Lipinski, J. Yuan, G. Kroemer, Cell death assays for drug discovery, Nat. Rev. Drug Discov. 10 (2011) 221-237.

DOI: 10.1038/nrd3373

[4] F.M. Balis, Evolution of anticancer drug discovery and the role of cell-based screening, J. Natl. Cancer Inst. 94 (2002) 78-79.

[5] W.H. Zimmermann, C. Fink, D. Kralisch, U. Remmers, J. Weil, T. Eschenhagen, Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes, Biotechnol. Bioeng. 68 (2000) 106-114.

DOI: 10.1002/(sici)1097-0290(20000405)68:1<106::aid-bit13>3.0.co;2-3

[6] E. Cukierman, R. Pankov, K.M. Yamada, Cell interactions with three-dimensional matrices, Curr. Opin. Cell Biol. 14 (2002) 633-640.

DOI: 10.1016/s0955-0674(02)00364-2

[7] M. Honda, T.J. Fujimi, S. Izumi, K. Izawa, M. Aizawa, H. Morisue, T. Tsuchiya, N. Kanzawa, Topographical analyses of proliferation and differentiation of osteoblasts in micro- and macropores of apatite-fiber scaffold, J. Biomed. Mater. Res. A 94 (2010).

DOI: 10.1002/jbm.a.32779

[8] J.C. Mei, A.Y. Wu, P.C. Wu, N.C. Cheng, W.B. Tsai, J. Yu, Three-dimensional extracellular matrix scaffolds by microfluidic fabrication for long-term spontaneously contracted cardiomyocyte culture, Tissue Eng. Part A 20 (2014) 2931-2941.

DOI: 10.1089/ten.tea.2013.0549

[9] J.U. Lind, T.A. Busbee, A.D. Valentine, F.S. Pasqualini, H. Yuan, M. Yadid, S.J. Park, A. Kotikian, A.P. Nesmith, P.H. Campbell, J.J. Vlassak, J.A. Lewis, K.K. Parker, Instrumented cardiac microphysiological devices via multimaterial three-dimensional printing, Na.t Mater. 16 (2017).

DOI: 10.1038/nmat4782

[10] N.M. Mordwinkin, P.W. Burridge, J.C. Wu, A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards, J. Cardiovasc. Transl. Res. 6 (2013) 22-30.

DOI: 10.1007/s12265-012-9423-2

[11] D. Sinnecker, K.L. Laugwitz, A. Moretti, Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing, Pharmacol. Ther. 143 (2014) 246-252.

DOI: 10.1016/j.pharmthera.2014.03.004

[12] M. Larsen, V.V. Artym, J.A. Green, K.M. Yamada, The matrix reorganized: extracellular matrix remodeling and integrin signaling, Curr. Opin. Cell Biol. 18 (2006) 463-471.

DOI: 10.1016/j.ceb.2006.08.009

[13] M. Kawata, H. Uchida, K. Itatani, I. Okada, S. Koda, M. Aizawa, Development of porous ceramics with well-controlled porosities and pore sizes from apatite fibers and their evaluations, J. Mater. Sci. Mater. Med. 15 (2004) 817-823.

DOI: 10.1023/b:jmsm.0000032823.66093.aa

[14] M. Aizawa, H. Shinoda, H. Uchida, I. Okada, T.J. Fujimi, N. Kanzawa, H. Morisue, M. Matsumoto, Y. Toyama, In vitro biological evaluations of three-dimensional scaffold developed from single-crystal apatite fibres for tissue engineering of bone, Phosph. Res. Bull. 17 (2004).

DOI: 10.3363/prb1992.17.0_262

[15] A. Habara-Ohkubo, Differentiation of beating cardiac muscle cells from a derivative of P19 embryonal carcinoma cells, Cell Struct. Funct. 21 (1996) 101-110.

DOI: 10.1247/csf.21.101

[16] M.A. Rudnicki, G. Jackowski, L. Saggin, M.W. McBurney, Actin and myosin expression during development of cardiac muscle from cultured embryonal carcinoma cells, Dev. Biol. 138 (1990) 348-358.

DOI: 10.1016/0012-1606(90)90202-t

[17] N. Kanzawa, H. Takano, K. Yasuda, M. Takahara, M. Aizawa, Studies on connexin 43, a gap-junction protein, in P19 embryonal carcinoma cells after culture on an apatite fiber scaffold, Key Eng. Mater. 696 (2016) 230-233.

DOI: 10.4028/www.scientific.net/kem.696.230

[18] K. Yasuda, H. Ishii, M. Takahara, M. Aizawa, N. Kanzawa, P19.CL6 cells cultured in apatite-fiber scaffold differentiate into cardiomyocytes, Key Eng. Mater. 631 (2014) 295-299.

DOI: 10.4028/www.scientific.net/kem.631.295

[19] H. Morisue, M. Matsumoto, K. Chiba, H. Matsumoto, Y. Toyama, M. Aizawa, N. Kanzawa, T.J. Fujimi, H. Uchida, I. Okada, Novel apatite fiber scaffolds can promote three-dimensional proliferation of osteoblasts in rodent bone regeneration models, J. Biomed. Mater. Res. A 90 (2009).

DOI: 10.1002/jbm.a.32147

[20] C.A. Schneider, W.S. Rasband, K.W. Eliceiri, NIH Image to ImageJ: 25 years of image analysis, Nat. Methods. 9 (2012) 671-675.

DOI: 10.1038/nmeth.2089

[21] C. Grépin, L. Robitaille, T. Antakly, M. Nemer, Inhibition of transcription factor GATA-4 expression blocks in vitro cardiac muscle differentiation, Mol. Cell. Biol. 15 (1995) 4095-4102.

DOI: 10.1128/mcb.15.8.4095

[22] G. Wang, H.I. Yeh, J.J. Lin, Characterization of cis-regulating elements and trans-activating factors of the rat cardiac troponin T gene, J. Biol. Chem. 269 (1994) 30595-30603.

DOI: 10.1016/s0021-9258(18)43855-0

[23] X. Shen, Q. Yang, P. Jin, X. Li, Alpha-lipoic acid enhances DMSO-induced cardiomyogenic differentiation of P19 cells, Acta Biochim. Biophys. Sin. (Shanghai) 46 (2014) 766-773.

DOI: 10.1093/abbs/gmu057

[24] R. Saito, Y. Ishii, R. Ito, K. Nagatsuma, K. Tanaka, M. Saito, H. Maehashi, H. Nomoto, K. Ohkawa, H. Mano, M. Aizawa, H. Hano, K. Yanaga, T. Matsuura, Transplantation of liver organoids in the omentum and kidney, Artif. Organs 35 (2011) 80-83.

DOI: 10.1111/j.1525-1594.2010.01049.x

[25] M. Vanderheyden, L. Defize, Twenty one years of P19 cells: what an embryonal carcinoma cell line taught us about cardiomyocyte differentiation, Cardiovasc. Res. 58 (2003) 292-302.

DOI: 10.1016/s0008-6363(02)00771-x

[26] A. Astashkina, B. Mann, D.W. Grainger, A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity, Pharmacol. Ther. 134 (2012) 82-106.

DOI: 10.1016/j.pharmthera.2012.01.001